perusinsuliini

Perusinsuliini, also known as basal insulin, is a long-acting form of insulin used in the management of diabetes. It is designed to provide a steady background level of insulin throughout the day and night, mimicking the natural, continuous secretion of insulin by the pancreas. This steady release helps to regulate blood glucose levels between meals and during sleep, preventing excessive rises in blood sugar.

There are two main types of perusinsuliini: intermediate-acting insulin and long-acting insulin. Intermediate-acting insulins, such as NPH insulin, typically begin to work within 1 to 3 hours, peak in effect after 6 to 10 hours, and last for 12 to 18 hours. Long-acting insulins, including glargine, detemir, and degludec, have a more prolonged and even action, generally starting to work within 1 to 4 hours and providing a duration of effect of up to 24 hours or more, with no significant peak.

Perusinsuliini is typically administered once or twice daily via subcutaneous injection. It is a crucial component of many diabetes treatment regimens, particularly for individuals with type 1 diabetes, where the body produces little to no insulin, and for some individuals with type 2 diabetes who may not be able to produce enough insulin on their own. Its use, in conjunction with rapid-acting (bolus) insulin or oral medications, helps to achieve better glycemic control and reduce the risk of long-term diabetes complications. Dosage and type of perusinsuliini are individualized based on a patient's needs, lifestyle, and blood glucose monitoring results, and are determined by a healthcare professional.